Severe falciparum malaria (21 cases).
The incidence of severe falciparum malaria is increasing in the developed countries and mortality remains high despite progress in intensive care management and schizonticide treatment. Many authors emphasize the importance of exchange transfusion (EXT) in the most severe cases. We studied 21 cases (34 +/- 12 years, 6 females; SAPS: 8.4 +/- 3.7) of severe malaria (according to WHO criteria) consecutively admitted to ICU between 1985 and 1990: 3 patients underwent EXT. Twenty were febrile above 39 degrees C, 10 had cerebral malaria, 14 hepatic impairment, 8 acute renal failure, 5 pulmonary oedema. Nine patients required mechanical ventilation, 1 haemodialysis, 1 intracranial pressure monitoring. Mean parasitemia was 13%, 16 patients had thrombocytopenia less than 50 x 10(9)/l, 3 anemia less than 7 g/dl and 3 leucopenia less than 2.8 x 10(9)/l. Nineteen received quinine i.v., 1 mefloquine, 1 chloroquine. Sixteen patients received blood products transfusion, 3 were treated by EXT in addition. Twenty were cured and discharged from hospital without sequelae (mean stay: 14 days); 4 had nosocomial infection, 1 a splenic infarction. One patient (17-years-old; SAPS: 17; parasitemia: 7.8%) died 12 h after admission from non-cardiogenic pulmonary oedema with multi-organ failure. The literature and this study lead us to propose EXT in patients with unfavourable evolution after conventional treatment rather than in all the patients with a parasitemia above 10% at admission. A randomized study to compare conventional treatment in ICU with or without EXT is necessary.
Salord
F
F
Intensive Care Unit, Hôpital Croix-Rousse, Lyon, France.
Allaouchiche
B
B
Gaussorgues
P
P
Boibieux
A
A
Sirodot
M
M
Gerard-Boncompain
M
M
Biron
F
F
Peyramond
D
D
Robert
D
D
D000293:Adolescent; D000328:Adult; D002675:Child, Preschool; D002738:Chloroquine / Q000627:therapeutic use; D005078:Exchange Transfusion, Whole Blood; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007362:Intensive Care Units; D016779:Malaria, Cerebral / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D016778:Malaria, Falciparum / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D015767:Mefloquine / Q000627:therapeutic use; D008875:Middle Aged; D011803:Quinine / Q000627:therapeutic use; D012121:Respiration, Artificial; D012189:Retrospective Studies
D002738:Chloroquine; D011803:Quinine; D015767:Mefloquine